Physician profile
Anna E Lark
NPI 1508646688
$2,358.96
in general payments reported to CMS, 2019-2025
32 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.56 · 2024: $1,268 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $369.74 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $221.15 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $209.80 | 2024-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $195.02 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $194.75 | 2024-2025 | |
| Pfizer INC. | $188.38 | 2024-2025 | |
| Lilly USA, LLC | $149.93 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $96.83 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $72.90 | 2024-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.48 | 2024-2025 | Xifaxan |
| Amgen INC. | $65.77 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $52.96 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $48.89 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Nevro Corp. | $45.71 | 2024 | Senza |
| Phathom Pharmaceuticals, INC. | $39.15 | 2023-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $36.06 | 2024-2025 | Gvoke Hypopen |
| Dexcom, INC. | $35.70 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $27.48 | 2025 | Watchman Access System |
| Amneal Pharmaceuticals LLC | $23.81 | 2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $23.53 | 2025 | |
| Neos Therapeutics, Lp | $19.04 | 2024 | Adzenys Xr-Odt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.89 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $16.66 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.57 | 2024 | Quviviq |
| Inspire Medical Systems, INC. | $16.22 | 2025 | Inspire |
| Ironshore Pharmaceuticals INC. | $15.87 | 2024 | |
| Corcept Therapeutics | $15.69 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $15.42 | 2024 | Nexletol |
| Viatris Specialty LLC | $15.31 | 2025 | Yupelri |
| Mylan Specialty L.P. | $14.02 | 2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2024 | Eliquis |
| Axsome Therapeutics, INC. | $13.23 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.